| Autor: |
Aktimur, Sude H., Malkan, Umit Y., Eyupoglu, Damla N., Haznedaroglu, Ibrahim C., Kelkitli, Engin, Atay, Hilmi M., Gunes, Gursel, Etgul, Sezgin, Aslan, Tuncay, Goker, Hakan, Sayinalp, Nilgun, Aksu, Salih, Ozcebe, Osman I., Buyukasik, Yahya, Turgut, Mehmet |
| Přispěvatelé: |
OMÜ, İç Hastalıkları |
| Jazyk: |
angličtina |
| Rok vydání: |
2016 |
| Předmět: |
|
| Popis: |
Haznedaroglu, Ibrahim C./0000-0001-8028-9462; aktimur, sude hatun/0000-0002-7468-1721; Malkan, Umit Yavuz/0000-0001-5444-4895 WOS: 000388276400004 Ruxolitinib as a JAK1 and JAK2 inhibitor drug has recently been approved for the treatment of patients with high-or intermediate-risk myelofibrosis with symptomatic splenomegaly. Clinical development of ruxolitinib has currently focused on the Ph* negative myeloproliferative neoplastic disorders (MPN). The aim of this study is to assess the impact of ruxolitinib treatment on the clinical course of Ph* negative myeloproliferative disorders. Forty-three patients who were under ruxolitinib treatment and followed-up between years 1987-2015 in Hacettepe University Medical School Hematology Clinic and Ondokuz Mayis University Hematology Clinic with myeloproliferative disease without Philadephia chromosome translocation were retrospectively analyzed. The constitutional symptoms were decreased in 97% of patients after ruxolitinib treatment. The mean spleen sizes before and after ruxolitinib treatment were 229 +/- 35 versus 202 +/- 31 mm, respectively (p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
